MLYS Projected Dividend Yield

Mineralys Therapeutics Inc ( NASDAQ : MLYS )

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Co.'s product candidate, lorundrostat, is a proprietary, orally administered aldosterone synthase inhibitor that it is developing for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve blood pressure (BP) of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

21 YEAR PERFORMANCE RESULTS